The main ingredients of this product are: ciprofloxacin lactate. Its chemical name is: 1- cyclopropyl -6- fluoro-1,4- dihydro -4- oxo -7-(1- piperazinyl) -3- quinoline carboxylic acid lactate. Molecular formula: C17H18FN3O3 C3H6O3 Molecular weight: 421.43
It is forbidden for patients with allergic history to this product and any fluoroquinolones.
This product is for intravenous drip administration. For any patient, the dosage should be determined according to the degree and nature of infection, the sensitivity of pathogenic bacteria, the patient’s body resistance and liver function. Generally, the dosage for adults is 0.1-0.2g once every 12 hours, and the infusion time is at least 30 minutes per 0.2g. For severe infection or Pseudomonas aeruginosa infection, the dosage can be increased to 0.4g once, 2-3 times a day. Depending on the degree of infection. The treatment usually lasts for 7-14 days, and should be continued for at least 2 days after the symptoms of infection disappear. 1. Urinary tract infection: acute simple lower urinary tract infection for 5-7 days; Complex urinary tract infection 7-14 days; 2. Pneumonia and skin and soft tissue infection: 7-14 days; 3. Intestinal infection: 5-7 days; 4. Bone and joint infection: 4-6 weeks or longer; 5. Typhoid fever: 10th-14th.
This product is colorless or almost colorless clear liquid.
As a generic drug supplier in China, Feiyue Pharmaceutical can provide finished drugs such as Ciprofloxacin Lactate Injection
Packaging: 0.2g : 100ml
FEIYUE recruits agents worldwide, we can provide complete registration documents.
Used for infection of genitourinary system caused by sensitive bacteria: 1. Infection of genitourinary system, including simple and complex urinary tract infection, bacterial prostatitis, Neisseria gonorrhoeae urethritis or cervicitis (including those caused by enzyme-producing strains). 2. Respiratory tract infection, including acute attack of bronchial infection and pulmonary infection caused by sensitive gram-negative bacilli. 3. Gastrointestinal infection caused by Shigella, Salmonella, enterotoxin-producing Escherichia coli, Aeromonas hydrophila, Vibrio parahaemolyticus, etc. 4. Typhoid fever. 5. Bone and joint infection. 6. Skin and soft tissue infection. 7. Systemic infection such as sepsis.
1. Gastrointestinal reactions are common, which can be manifested as abdominal discomfort or pain, diarrhea, nausea or vomiting, indigestion, anorexia. If you find severe long-term diarrhea during treatment, you must consult a doctor, because it may be pseudomembranous enteritis, a serious gastrointestinal disease. Once this happens, the drug should be stopped immediately. Give appropriate treatment (such as vancomycin). Drugs for inhibiting gastrointestinal peristalsis are prohibited. 2. The central nervous system reaction can be dizziness, headache, lethargy or insomnia. In a few cases, peripheral hyperalgesia, increased intracranial pressure, ataxia, convulsion, anxiety, confusion, depression, hallucination, seizures, etc. Individual patients even have mental self-threatening behavior. Some patients can have these reactions at the first time, so they should stop the drug immediately and inform the doctor. 3. Allergic reaction: rash, itchy skin, drug fever, urticaria, and occasionally exudative erythema multiforme and angioneurotic edema. In some cases, laryngeal edema, dyspnea and anaphylactic shock can occur after the first medication, so anti-shock treatment should be given immediately. A few patients have photosensitivity reaction. 4. Occasionally: (1) Abnormal vision, impaired taste, tinnitus and hearing loss. (2) Hematuria, interstitial nephritis, hepatitis, liver necrosis and failure. (3) Phlebitis or thrombophlebitis. (4) Crystalline urine, more common in high-dose applications. (5) Joint pain, muscle pain, tenosynovitis and Achilles tendinitis. (6) Tachycardia, facial flushing, migraine and syncope. (7) Blood system effects: anemia, thrombocytopenia, leukopenia, eosinophilia, hemolytic anemia, changes in blood coagulation. (8) Skin punctate hemorrhage (petechiae) and blister formation, accompanied by hemorrhage (bleb) and crusted nodules (papules), stevens-Johnson and Yell syndrome. (9) Long-term and repeated application of this product can cause drug-resistant bacteria or yeast-like bacteria infection. 5. Abnormal laboratory data: A few patients may have elevated serum aminotransferase, alkaline phosphatase and cholestatic jaundice, especially in patients with liver damage, with elevated blood urea nitrogen, creatinine or bilirubin, and some patients may have hyperglycemia, crystallized urine and hematuria. 6. Ciprofloxacin can affect patients’ reaction ability to drive or operate machines, especially in patients who drink alcohol at the same time.
1. Urine alkalizer can reduce the solubility of this product in urine, leading to crystalline urine and nephrotoxicity. 2. When this product is combined with theophylline, it may be due to the competitive inhibition of cytochrome P450 binding site, resulting in a significant decrease in liver clearance of theophylline, a prolonged half-life of blood elimination (t 1/2β), an increase in blood drug concentration, and symptoms of theophylline poisoning, such as nausea, vomiting, tremor, restlessness, excitement, convulsions, palpitations, etc., so the blood drug concentration of theophylline should be determined and the dosage adjusted when combined. 3. The combination of cyclosporine and this product can increase the blood concentration of the former. It is necessary to monitor the blood concentration of cyclosporine and adjust the dose. 4. This product can enhance the anticoagulation effect of the anticoagulant warfarin when used together, and the prothrombin time of patients should be closely monitored when used together. 5. Probenecid can reduce the secretion of this product from renal tubules by about 50%. When used together, it can cause toxicity due to the increase of blood concentration of this product. 6. This product interferes with the metabolism of caffeine, which leads to the decrease of caffeine clearance, the prolongation of blood elimination half-life (t 1/2β), and may cause central nervous system toxicity. 7. Metoclopramide can accelerate the absorption of this product, but it has no effect on bioavailability. 8. Animal experiments have shown that high-dose quinolones combined with some NSAIDs can cause convulsions, and rapid intravenous injection can lead to hypotension.